Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other



Sharp Shalini Create: Alert

All | News | Filings
Date FiledTypeDescription
05/19/2023 4 Sharp Shalini (Director) has filed a Form 4 on NEUROCRINE BIOSCIENCES INC
Txns: Granted 4,290 options to buy @ $95.27, valued at $408.7k
Granted 2,100 restricted stock units @ $0
01/24/2023 4 Sharp Shalini (Director) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 4,444 shares @ $0
Granted 7,520 options to buy @ $45.66, valued at $343.4k
06/14/2022 4 Sharp Shalini (Director) has filed a Form 4 on Organon & Co.
Txns: Granted 5,640 options to buy @ $35.46, valued at $200k
06/08/2022 4 Sharp Shalini (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 18,500 options to buy @ $4.44, valued at $82.1k
05/20/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/18/2022 4 Sharp Shalini (Director) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 2,546 shares @ $0
Granted 3,688 options to buy @ $124.31, valued at $458.5k
06/08/2021 4 Sharp Shalini (Director) has filed a Form 4 on Organon & Co.
Txns: Granted 9,061 options to buy @ $36.05, valued at $326.6k
06/07/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/20/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/12/2021 4 Sharp Shalini (Director) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Granted 32,800 options to buy @ $8.07, valued at $264.7k
03/30/2021 4 Sharp Shalini (Director) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 2,424 shares @ $0
Granted 3,523 options to buy @ $164.98, valued at $581.2k
02/26/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/16/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/19/2020 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Sold 461 shares @ $88.24, valued at $40.7k
Sold 2,560 shares @ $88.54, valued at $226.7k
Sold 500 shares @ $88.38, valued at $44.2k
Sold 7,188 shares @ $88.38, valued at $635.3k
Sold 3,669 shares @ $88.38, valued at $324.3k
Exercised 500 options to buy @ $70.57, valued at $35.3k
Exercised 7,188 options to buy @ $67.55, valued at $485.5k
Exercised 3,669 options to buy @ $48.43, valued at $177.7k
06/08/2020 4 Sharp Shalini (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 12,000 options to buy @ $9.83, valued at $118k
06/05/2020 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Sold 10,234 shares @ $74.23, valued at $759.7k
Sold 2,564 shares @ $74.01, valued at $189.8k
Exercised 10,234 options to buy @ $48.43, valued at $495.6k
Exercised 2,564 options to buy @ $48.43, valued at $124.2k
06/03/2020 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Paid exercise price by delivering 348 shares @ $69.38, valued at $24.1k
05/20/2020 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Sold 19,593 shares @ $73.34, valued at $1.4M
Sold 2,392 shares @ $73.29, valued at $175.3k
Sold 3,221 shares @ $73.32, valued at $236.2k
Sold 3,907 shares @ $73.32, valued at $286.5k
Exercised 19,593 options to buy @ $70.57, valued at $1.4M
Exercised 3,221 options to buy @ $48.43, valued at $156k
Exercised 3,907 options to buy @ $70.57, valued at $275.7k
05/15/2020 4 Sharp Shalini (Director) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Granted 41,038 options to buy @ $6.62, valued at $271.7k
05/08/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2020 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Paid exercise price by delivering 248 shares @ $58.57, valued at $14.5k
03/03/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/04/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/16/2019 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 1,434 shares @ $0
09/17/2019 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Exercised 6,963 options to buy @ $0.81, valued at $5.6k
Exercised 24,880 options to buy @ $6.86, valued at $170.7k
07/30/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/19/2019 4 Sharp Shalini (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 11,610 options to buy @ $11.12, valued at $129.1k
06/04/2019 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Paid exercise price by delivering 346 shares @ $54.93, valued at $19k
05/22/2019 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Paid exercise price by delivering 381 shares @ $59.5, valued at $22.7k
05/07/2019 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 1,434 shares @ $0
04/23/2019 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Paid exercise price by delivering 248 shares @ $64.43, valued at $16k
03/20/2019 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Sold 14,800 shares @ $70, valued at $1M
Exercised 12,000 options to buy @ $6.86, valued at $82.3k
03/04/2019 4 Sharp Shalini (CFO & Executive Vice President) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 8,000 shares @ $0
Paid exercise price by delivering 981 shares @ $67.55, valued at $66.3k
Granted 23,000 options to buy @ $67.55, valued at $1.6M
11/13/2018 4 Sharp Shalini (Director) has filed a Form 4 on SUTRO BIOPHARMA, INC.
Txns: Granted 26,033 options to buy @ $14.23, valued at $370.4k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy